GT Biopharma Inc. (NASDAQ:GTBP) saw its stock rise 4.1% on Wednesday after announcing that its Phase 1 study for its lead ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

Biogen and Eisai have announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an ...

Over the course of the patient's treatment, there were opportunities to recognize the error and prevent the patient's catastrophic results.

Patients who take omalizumab prior to starting oral immunotherapy (OIT) may skip much of the latter treatment’s onerous dose ...

The MWF dosing option was approved under the Real-Time Oncology Review program based on data from the intramuscular administration part of a phase 2/3 trial. The Food and Drug Administration (FDA) has ...

The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...

Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...

An American Academy of Pediatrics study looked at how to prevent dosing errors. — -- More than 80 percent of parents have made at least one dosing error when ...

A common cause of acute kidney injury (AKI) is sepsis, which makes appropriate dosing of antibiotics in these patients essential. Drug dosing in critically ill patients with AKI, however, can be ...

A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...